Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Hanks, D. Justins (1992)
Cancer pain: managementThe Lancet, 339
Liana Bruce, K. Bajwa, Justin Markle, J. Timbie, C. Zacker, K. Schulman (2001)
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone diseaseSupportive Care in Cancer, 9
Lise Lucas, A. Lipman (2002)
Recent advances in pharmacotherapy for cancer pain management.Cancer practice, 10 Suppl 1
R. Coleman (1997)
Skeletal complications of malignancyCancer, 80
P. Conte, J. Latreille, L. Mauriac, F. Calabresi, R. Santos, D. Campos, J. Bonneterre, G. Francini, J. Ford (1996)
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 9
G. Hortobagyi, R. Theriault, A. Lipton, L. Porter, D. Blayney, C. Sinoff, H. Wheeler, Joseph Simeone, J. Seaman, Robert Knight, M. Heffernan, K. Mellars, D. Reitsma (1998)
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 6
R. Daut, C. Cleeland (1982)
The prevalence and severity of pain in cancerCancer, 50
L. Pickering, J. Mansi (2002)
The Role of Bisphosphonates in Breast Cancer Management: Review ArticleCurrent Medical Research and Opinion, 18
C. Ripamonti, E.D. Dickerson (2001)
Strategies for the treatment of cancer pain in the new millenniumDrugs, 61
J. Green, K. Müller, K. Jaeggi (1994)
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 9
Alfredo Berruti, L. Dogliotti, R. Bitossi, Giuseppe Fasolis, G. Gorzegno, Maurizio Bellina, M. Torta, F. Porpiglia, Dario Fontana, Alberto Angeli (2000)
Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.The Journal of urology, 164 4
S. Mercadante (1996)
Malignant bone pain: pathophysiology and treatmentPain, 69
SP Jagdev, R. Coleman, CM Shipman, A. Rostami-H, P. Croucher (2001)
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelBritish Journal of Cancer, 84
P. Staats (2002)
Bonica's Management of Pain.Anesthesiology, 97
F. Pons, D. Fuster (2002)
Under-utilization of radionuclide therapy in metastatic bone pain palliation.Nuclear medicine communications, 23 4
K. Walker, S. Medhurst, B. Kidd, M. Glatt, M. Bowes, Sadhana Patel, K. McNair, A. Kesingland, Jonathan Green, O. Chan, A. Fox, L. Urbán (2002)
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer painPain, 100
L. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, J. Mackey, J. Apffelstaedt, M. Hussein, R. Coleman, D. Reitsma, J. Seaman, Bee Chen, Yvonne Ambros (2001)
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.Cancer journal, 7 5
J. Berenson, L. Rosen, A. Howell, Lester Porter, R. Coleman, W. Morley, R. Dreicer, S. Kuross, A. Lipton, J. Seaman (2001)
Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastasesCancer, 91
J. Green (2003)
Antitumor effects of bisphosphonatesCancer, 97
H. Neville-Webbe, I. Holen, Robert Coleman (2002)
The anti-tumour activity of bisphosphonates.Cancer treatment reviews, 28 6
N. Janjan (2001)
Bone metastases: approaches to management.Seminars in oncology, 28 4 Suppl 11
N. Zojer, A. Keck, M. Pecherstorfer (1999)
Comparative Tolerability of Drug Therapies for Hypercalcaemia of MalignancyDrug Safety, 21
K. Wellington, K.L. Goa (2003)
Zoledronic acid: a review of its use in the malignancy of bone metastases and hypercalcaemia of malignancyDrugs, 63
R. Coleman (1994)
Evaluation of bone disease in breast cancerThe Breast, 3
F. Saad, D. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. Chin, J. Vinholes, J. Goas, Bee Chen (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.Journal of the National Cancer Institute, 94 19
G. Hortobagyi, R. Theriault, L. Porter, D. Blayney, A. Lipton, C. Sinoff, H. Wheeler, J. Simeone, J. Seaman, Robert Knight, M. Heffernan, D. Reitsma, I. Kennedy, S. Allan, K. Mellars (1996)
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.The New England journal of medicine, 335 24
N. Pavlakis, Robert Schmidt, M. Stockler (2005)
Bisphosphonates for breast cancer.The Cochrane database of systematic reviews, 1
P. Tassone, S. Forciniti, E. Galea, Giovanni Morrone, Maria Turco, V. Martinelli, P. Tagliaferri, Salvatore Venuta (2000)
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell linesLeukemia, 14
B. Hillner, J. Ingle, J. Berenson, N. Janjan, K. Albain, A. Lipton, G. Yee, J. Biermann, R. Chlebowski, D. Pfister (2000)
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast CancerJournal of Clinical Oncology, 18
R. Simon (1989)
Optimal two-stage designs for phase II clinical trials.Controlled clinical trials, 10 1
cancer patients. Bisphosphonates are recommended in treating skeletal complications and there is evidence that they also control pain. Objective: To investigate the effects of zoledronic acid, a potent nitrogen-containing bisphosphonate, in reducing pain in patients with advanced breast cancer and bone metastases. Patients and methods: Thirty-two patients (age range 37–79 years, median 56 years) with histologically proven breast cancer and bone metastases received a 15-minute infusion of zoledronic acid 4mg every 4 weeks for a mean of eight cycles (range 1–13) in a phase II pilot study. The primary efficacy endpoint was the control of pain as determined by changes in pain and analgesic scores. Results: Zoledronic acid substantially reduced pain scores compared with baseline, with over 80% of patients reporting mild or no pain at the end of the trial (82% had moderate to very severe pain on entry). The percentage of patients requiring no analgesics increased from 9% to 35% following zoledronic acid treatment. At baseline, 47% of patients required opioids to control pain, whereas 27% required opioids at the end of the trial. Zoledronic acid appeared to be well tolerated, with no patients reporting serious adverse events. Conclusion: These results support previous data indicating that zoledronic
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.